tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Buy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development
PremiumRatingsBuy Rating for Insmed: Promising Market Potential and Strategic Advancements in TPIP Development
6d ago
Insmed strength on United Therapeutics read through ‘warranted,’ says BofA
Premium
The Fly
Insmed strength on United Therapeutics read through ‘warranted,’ says BofA
7d ago
Optimistic Buy Rating for Insmed’s TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment
Premium
Ratings
Optimistic Buy Rating for Insmed’s TPIP Driven by Promising TETON-2 Trial Results and Market Potential in IPF Treatment
7d ago
Insmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
PremiumRatingsInsmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
20d ago
Insmed price target raised to $135 from $111 at JPMorgan
Premium
The Fly
Insmed price target raised to $135 from $111 at JPMorgan
20d ago
Insmed initiated with an Outperform at William Blair
Premium
The Fly
Insmed initiated with an Outperform at William Blair
20d ago
H.C. Wainwright doubles Insmed target to $240 on ‘pipeline-in-a-pill’ potential
PremiumThe FlyH.C. Wainwright doubles Insmed target to $240 on ‘pipeline-in-a-pill’ potential
26d ago
C3 AI downgraded, Capri upgraded: Wall Street’s top analyst calls
Premium
The Fly
C3 AI downgraded, Capri upgraded: Wall Street’s top analyst calls
27d ago
Insmed price target raised to $140 from $133 at UBS
Premium
The Fly
Insmed price target raised to $140 from $133 at UBS
27d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100